Evidence-based pharmacotherapy of panic disorder: An update
Date
2012
Authors
Batelaan N.M.
Van Balkom A.J.L.M.
Stein D.J.
Journal Title
Journal ISSN
Volume Title
Publisher
Abstract
The evidence-based pharmacotherapy of panic disorder continues to evolve. This paper reviews data on first-line pharmacotherapy, evidence for maintenance treatment, and management options for treatment-refractory patients. A Medline search of research on pharmacotherapy was undertaken, and a previous systematic review on the evidence-based pharmacotherapy of panic disorder was updated. Selective serotonin reuptake inhibitors remain a first-line pharmacotherapy of panic disorder, with the serotonin noradrenaline reuptake inhibitor venlafaxine also an acceptable early option. Temporary co-administration of benzodiazepines can be considered. Maintenance treatment reduces relapse rates, but further research to determine optimal duration is needed. For patients not responding to first-line agents several pharmacotherapy options are available, but there is a notable paucity of data on the optimal choice. © 2011 CINP.
Description
Keywords
Panic disorder, pharmacotherapy, treatment
Citation
International Journal of Neuropsychopharmacology
15
3
403
415
15
3
403
415